abbott see strength growth driver
rais fve
page full analyst note jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
abbott expand medic devic footprint addit
st jude medic continu improv profit
segment nutrit devic diagnost establish
pharmaceut although abbott made progress last
six year still lag key rival profit measur despit
compet busi character attract
abbott effort improv effici includ streamlin
distribut channel build facil lower-cost locat
like china india demonstr success
still room improv look compani
consolid profit think abbott emphasi margin
improv pay next five year
like manag turn attent new sourc
growth view abbott new freestyl libr blood glucos
monitor offer compel innov anticip abbott
substanti footprint latin america russia establish
pharmaceut product also deliv steadi growth
also applaud sale abbott epp busi develop
market optic unit reshuffl put abbott
favor posit focu faster grow market
brand gener emerg market addit st jude
heart-focus portfolio along smaller tuck-in significantli
broaden abbott cardiac devic product offer rais
firm abil compet hospit client seek winnow
still forecast mid-single-digit revenu growth abbott
think potenti firm goos growth key
product line meantim see opportun
abbott enhanc effici fuel earn growth address
situat
larg
manag control abbott exceed expect
close profit gap competit set upsid
valuat
low-hang fruit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note ep calcul divid net incom averag number common
abbott manufactur market medic devic blood glucos
monitor kit nutrit healthcar product diagnost product
equip brand gener drug product includ pacemak
stent cathet infant formula nutrit liquid adult molecular
point-of-car diagnost equip abbott deriv approxim
sale outsid unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abbott see strength growth driver
rais fve jul
abbott lab post stronger expect second-quart
perform weve moder rais fair valu
per share adjust project key
growth driver upward befit size
breadth abbott benefit wax new product
cycl off-set wane product cycl
robust growth fuel innov structur heart
diabet electrophysiolog heart failur outpac
establish pharmaceut nutrit
vascular cardiac rhythm manag product line
pleas see steadi stream new product
indic revenue growth medic devic segment
expect continu midterm especi
product begin tackl adopt
curv particular mitraclip indic expans
function mitral regurgit led stronger uptak
quarter wed anticip weve long thought
penetr fmr market signific opportun
transcathet mitral valv repair replac
technolog weve also held temper view adopt
cardiologist time-frame surgic intervent
valuabl unpredict patient patient
surg mitraclip growth suggest us
signific underli demand therapi
suspect intervent cardiologist also favor
technolog especi procedur
angioplasti grow slowli next-
gen mitraclip recent approv food drug
administr fda support strong
adopt version address
shortcom earlier version
navig size deploy
note posit surround mitraclip
perform also bode well edward lifesci
pascal devic launch europ year
nonetheless abbott still enjoy enviabl headstart
 edward like receiv regulatori
approv
separ also impress strength flash
glucos monitor libr saw growth year
year libr offer larg type diabet popul real
improv tradit glucos meter requir
multipl fingerstick day manag indic
abbott plan roll expand capac year
anticip libr current review fda
offer featuresreal-tim alert glucos read
rang via bluetooth alarm indic loss connect
sensorthat make experi
similar continu glucos monitor dexcom
final recent clinic data libr demonstr type
patient use devic multipl daili insulin
inject abl significantli lower blood
glucos level outcom data along
competit price support on-go penetr
type market
follow consist strong result last coupl
quarter rais fair valu estim
per share reflect optimist project
key growth driver expect penetr larg
underserv patient popul continu expect
top-lin strength domest launch freestyl
libr on-going adopt alin system
comprehens test panel innov structur
heart heart failur electrophysiolog
neuromodul area weak
competitor introduc new product project
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium
bullish scenario put abbott valu per
share case assum abbott averag
top-lin growth thank addit st jude aler
well outsiz gain pediatr adult nutrit
intern double-digit growth structur heart
greater penetr cardiovascular devic oversea
also assum abbott reach level manufactur
expens compar key competitor like dr
reddi along oper margin
peak
bear case abbott per share
scenario top line averag annual howev
assum declin stent sale boston scientif
offer superior technolog long haul
mute perform mitraclip edward enter
nutrit
low-single-digit growth diagnost assum abbott
rais oper margin basi point
think addit st jude push abbott toward
wider side narrow moat fulli convinc
abbott tip wide moat categori
especi firm nurtur kind on-going
occasion revolutionari innov necessari
secur reimburs longer term
case abbott one three four competitor
domin market includ nutrit cardiac
nutrit freestyl libr destin therapi
fuel mitraclip
still see potenti improv profit abbott
remain busi turn key factor
valuat consolid basi abbott oper
margin significantli trail key competitor
variou busi segment good news abbott
compet sever market offer rel high
margin includ nutrit brand gener drug
cardiovascular devic addit abbott alreadi
begun effort improv product effici
streamlin distribut channel build new facil
lower-cost locat like china india expect
abbott partial close oper margin gap
project basi point improv firm
leverag distribut infrastructur built
penetr emerg market across product
segment extract cost synergi recent
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
monitor coronari stent immunoassay
market abbott particip ration oligopoli
enjoy benefit intang asset
think nutrit busi one moatiest
part new abbott wield leadership posit
highli consolid market estim
billion world-wide asid strength develop
market firm face brighter growth prospect
emerg market growth middle-class
famili spur demand pediatr adult nutrit
product thank strong similac ensur brand
abbott advantag posit introduc new
formul line extens penetr new
market abbott made substanti invest earli
build infrastructur emerg market includ
new ventur new zealand-bas build
large-scal dairi farm hub china firm
reap reward invest expand
build block experi nutrit
also play well appli abbott
establish pharmaceut product segment sold
outsid busi frequent call brand
gener oper like consum busi
gener mainli sold less develop market
often lack well-develop infrastructur distribut
instead abbott must sell product directli pharmaci
chain physician result brand recognit
reput key factor abbott leverag sell
fragment market also translat less price
pressur abbott could chang longer term
emerg market turn tender system
character develop nation howev chang
remain
near medium term think abbott benefit
addit st jude impress expertis
cardiac rhythm manag structur heart heart
failur howev juri still abbott abil
nurtur renew innov area long haul
thu far abbott done credibl job commerci
alreadi st jude pipelin less
confid abbott gener greater
leap
innov base
track record earlier
final abbott reli intellectu properti ward
competitor devic diagnost segment
think firm earn narrow moat four
segment translat narrow moat entir
potenti price pressur variou sourc
across abbott market exampl trend toward
brand gener declin
reimburs vascular devic firm
invest pipelin lead stream new
product fortifi price power medium
term abbott scale divers help steadi moat
trend anticip strength cardiac devic segment
divis diabet busi off-set
current weak neuromodul molecular
abbott abil deploy robust predict cash
flow
busi toward acquisit
partnership help replenish pipelin
support abbott growth also keep smaller
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
compani gain critic mass encroach
abbott narrow moat abbott develop
revolutionari devic pipelin candid demonstr
strongli favor clinic outcom acquir
extens collect med-tech product allow
comprehens partner hospit
consid turn moat trend rate posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oabbott xienc stent remain powerhous
well-
drug-elut stent market thank
establish record safeti efficaci
oaggress cost-cut plan propel abbott
bottom-lin growth quickli top-lin growth
oabbott sale establish pharma busi
develop market acquisit
veropharm put abbott brand gener
busi strong posit benefit grow
demand emerg market
oclin data drug-elut stent altern
therapi put crimp percutan coronari
procedur medic therapi coronari bypass
gain favor
oabbott face uphil battl molecular
diagnost arena must go head-to-head
market leader roch along energet
upstart like
oslow growth fall birth rate china offer
abbott nutrit
segment could damp nutrit firm
final overcam regulatori chang china
drag growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
larg acquisit st jude medic aler
abbott enjoy less financi flexibl
medium term issu debt share financ
purchas sale vision-car busi
purchas st jude abbott debt/ebitda hover around
time end two year
manag brought debt level closer time
end expect debt/ebitda fall
time remain comfort abbott
estim interest coverag ebitda/interest time
coverag rise ensu year
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium like compani
involv medic technolog abbott vulner
threat revolutionari innov competitor
particularli issu medic devic
diagnost busi despit abbott recent effort
better insul recal like infant formula
recal china risk product qualiti issu
recal remain damag firm brand
relationship medic profession hospit
custom payer tighten purs string abbott could
see greater price pressur furthermor hospit
cardiac therapeut area abbott could find
disadvantag compar key rival
johnson johnson final abbott oper
scrutini food drug administr
well regulatori agenc oversea lead
delay product approv product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
american fund growth fund amer
capit research manag compani
legal gener
new york mellon corp
share
fund
share
fund
overal rate abbott stewardship standard
compani made impress purchas
past decad includ purchas
billion brought humira sever
recent acquisit piram st jude
medic remain promis yet fulli match
purchas price remain skeptic acquisit
aler point-of-car diagnost seem
add compel valu abbott technolog
distribut bargain posit proprietari
pharma product spun expect
manag new focu remain busi
result greater effici profit
watch care see abbott abl realiz
potenti acquisit made avoid less
mile white took helm ceo chairman
board follow year tenur abbott date
back provid experi need handl
compani mani oper line find somewhat
worrisom white allow non-abbvie-rel
busi becom flabbi watch white
made progress profit front past
sever year still plenti room
improv abbott catch key
competitor board heavili weight
toward independ former execut
publicli trade firm chicago area particularli
pleas see stark former ceo st jude join
board expect experi lead st jude ramp
innov could posit influenc abbott
said think room improv
compens polici -- move away benchmark
involv adjust earn per share ebit
measur focus return invest capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abbott see strength growth driver
rais fve jul
abbott lab post stronger expect second-quart
perform weve moder rais fair valu
per share adjust project key
growth driver upward befit size
breadth abbott benefit wax new product
cycl off-set wane product cycl
robust growth fuel innov structur heart
diabet electrophysiolog heart failur outpac
establish pharmaceut nutrit
vascular cardiac rhythm manag product line
pleas see steadi stream new product
indic revenue growth medic devic segment
expect continu midterm especi
product begin tackl adopt
curv particular mitraclip indic expans
function mitral regurgit led stronger uptak
quarter wed anticip weve long thought
penetr fmr market signific opportun
transcathet mitral valv repair replac
technolog weve also held temper view adopt
cardiologist time-frame surgic intervent
valuabl unpredict patient patient
surg mitraclip growth suggest us
signific underli demand therapi
suspect intervent cardiologist also favor
technolog especi procedur
angioplasti grow slowli next-
gen mitraclip recent approv food drug
administr fda support strong
adopt version address
shortcom earlier version
navig size deploy
note posit surround mitraclip
perform also bode well edward lifesci
pascal devic launch europ year
nonetheless abbott still enjoy enviabl headstart
 edward like receiv regulatori
approv
separ also impress strength flash
glucos monitor libr saw growth year
year libr offer larg type diabet popul real
improv tradit glucos meter requir
multipl fingerstick day manag indic
abbott plan roll expand capac year
anticip libr current review fda
offer featuresreal-tim alert glucos read
rang via bluetooth alarm indic loss connect
sensorthat make experi
similar continu glucos monitor dexcom
final recent clinic data libr demonstr type
patient use devic multipl daili insulin
inject abl significantli lower blood
glucos level outcom data along
competit price support on-go penetr
type market
abbott deliv surpris chang
abbott post first-quart result fell slightli short
revenu expect comfort
project solid underli growth across abbott four
divis hold steadi fair valu
estim abbott face substanti foreign currenc
headwind deliv strong organ revenu growth
coupl good expens control ad
basi point improv quarterli oper margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
year year see littl chang narrow moat
rate especi abbott leverag strength
nutrit diagnost diabet unit
standout product includ freestyl libr
continu glucos monitor mitraclip transcathet
mitral valv repair devic deliv double-
digit growth think libr growth intern market
past initi exponenti rate smaller base
settl sustain growth low
trend teen come year support
spread reimburs libr remain
earlier stage adopt still expect growth
low year pleas see firm
alreadi shepherd next-gener libr food
drug administr launch europ user-
friendli libr compel price help
sway diabet away multipl glucos meter
read throughout day
remain guard mitraclip associ
mix factor one hand product recent
receiv new indic treatment function mitral
regurgit allow abbott tap larger patient
pool congest heart failur versu patient
degen mr also result coapt studi
make strong case mitraclip therapi medic
hand mitra-fr studi suggest devic
ultim effect prognosi
thu think abbott like see robust
mitraclip growth thank new indic especi
medicar establish reimburs function
mr indic believ product remain best suit
subset patient certain valv anatomi
mitraclip also hamper procedur time continu
substanti especi compar
analysi mitraclip
degen mr suggest mitraclip procedur
unprofit hospit -- even unprofit
tavr procedur said note lose
money tavr doesnt seem stop hospit
start program
mitraclip perform far revenu growth
reimburs lead us believ signific
demand tmv repair technolog howev consid
specif drawback mitraclip devic
competit product introduc that easier use
faster use better suit patient wed expect
take share abbott think edward lifesci
pascal devic could offer attract altern sinc
product recent receiv regulatori approv europ
keep eye much pascal cut
mitraclip perform market
creativ
final two addit product line stood us
quarter competit reason first abbott cardiac
rhythm manag busi fell nearli year
year wed alreadi harbor concern abbott abil
innov market longer term addit
specul
contract center tyrx antibacteri envelop
pull addit devic
offer layer insul competitor
quarter alreadi sign
 hospit tyrx contract american
colleg cardiolog confer last month new clinic
data tyrx demonstr product reduc major
infect pocket infect
expect impress data spur hospit
medtron risk-bas contract near mid-
second legaci st jude neuromodul busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
need transplant sever thousand get one
remain patient could benefit lvad therapi
hand abbott saw soft domest
fourth-quart cardiac rhythm manag busi
declin year year recogn abbott
especi strong fourth-quart perform prior-
year period launch mri-compat devic
howev think firm disadvantag
curiou see abbott pipelin compet
directli boston scientif
front
abbott manag chalk weak
 unit relat larger market growth
entir convinc boston seen
strong adopt s-icd leadless pacemak
respect weve discuss suspect
medtron effort sign hospit risk-
base contract tyrx antibacteri envelop
tradit devic could affect tradit
competit dynam market better
sens market boston report
next month meantim detail medtron
novel approach chang payment model
strategi help enhanc medtron
value-bas payment reinforc wide moat
becom rocki could take time fix
last year product line grew midsingl digit
significantli lag neuromodul market
first quarter year neuromodul revenu fell
year year specul number sale
rep depart along key member
abbott
manag contend seek increas
neuromodul sale forc howev
suspect firm primarili tri rebuild salesforc
rather ad increment
chang fve jan
finish fourth quarter full year close
expect top bottom line
leav fair valu estim unchang although growth
nutrit seem moder recoveri seen
chines infant formula market adopt new
product includ alin diagnost instrument
penetr freestyl libr continu glucos monitor
new product indic cardiac area drove
fourth-quart organ revenu solid
see littl chang think abbott narrow
econom moat point
remain optimist abbott diabet busi
thank european launch next-gen libr
featur alarm signal low high blood glucos level
real time well medicar decis cover
origin libr user-friendli libr
price set product apart competitor also
favor new destin therapi indic
heartmat left ventricular assist devic patient
advanc heart failur lvad origin
indic short-term use wait heart
transplant long-term destin therapi attract
opportun roughli patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
